AN2 Therapeutics Management
Management criteria checks 3/4
AN2 Therapeutics' CEO is Eric Easom, appointed in Nov 2019, has a tenure of 4.5 years. total yearly compensation is $3.34M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 4.06% of the company’s shares, worth $2.96M. The average tenure of the management team and the board of directors is 3.6 years and 4.3 years respectively.
Key information
Eric Easom
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 17.2% |
| CEO tenure | 4.5yrs |
| CEO ownership | 4.1% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$575k | -US$65m |
| Sep 30 2023 | n/a | n/a | -US$60m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$3m | US$481k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$377k | -US$28m |
Compensation vs Market: Eric's total compensation ($USD3.34M) is above average for companies of similar size in the US market ($USD661.60K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Easom (55 yo)
4.5yrs
Tenure
US$3,342,848
Compensation
Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc., and has been its CEO, President & Director from November 19, 2019. He served as Senior Director of Business Development & Marketing of InteKrin Th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder & Chairman of the Board | 7yrs | US$179.64k | 1.69% $ 1.2m | |
| Co-founder | 4.5yrs | US$3.34m | 4.06% $ 3.0m | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 4.5yrs | US$1.52m | 0.010% $ 7.6k | |
| Chief Medical Officer | 4.5yrs | US$1.45m | 0.072% $ 52.3k | |
| Co-Founder & Senior Clinical Advisor | no data | no data | no data | |
| Co-Founder & Head of Biology | no data | no data | no data | |
| Chief Legal Officer & Secretary | 1.7yrs | US$1.66m | no data | |
| Chief Development Officer | 4.5yrs | no data | 0.0025% $ 1.8k | |
| Chief Strategy Officer | 2.8yrs | no data | 0.0064% $ 4.7k | |
| Senior Vice President of Regulatory Affairs & Quality | 1.8yrs | no data | no data | |
| VP of Finance & Corporate Controller | less than a year | no data | no data |
3.6yrs
Average Tenure
55yo
Average Age
Experienced Management: ANTX's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder & Chairman of the Board | 7yrs | US$179.64k | 1.69% $ 1.2m | |
| Co-founder | 4.5yrs | US$3.34m | 4.06% $ 3.0m | |
| Independent Director | 2.3yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$153.14k | 0% $ 0 | |
| Independent Director | 2yrs | US$142.14k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$146.14k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$157.14k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$145.64k | 0.077% $ 55.7k |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: ANTX's board of directors are considered experienced (4.3 years average tenure).